In January 2026, one negotiation cut Eliquis from a $521 sticker to $231 overnight — same pill. So somebody was choosing that number all along. This capstone follows the rebate chain, the middlemen, and the patent wall, with the insulin, EpiPen, inhaler and GLP-1 stories as evidence. Every figure dated and sourced.
Structured with AI assistance and strictly fact-checked by our editorial team against primary sources. How we work →
This is a capstone, so the table follows the machine instead of a map: each row is one link in the chain that turns a factory price into your copay. Figures come from CMS's negotiated-price fact sheet, FTC staff reports and complaint filings, GAO audits, peer-reviewed journals, and RAND/ASPE international comparisons — each anchored to the year of the underlying data.
| Link in the chain | Figure | Context | Source |
|---|---|---|---|
| The sticker — manufacturers | $521 → $231 overnight | Eliquis, the blood thinner nearly 4 million Medicare patients take: $521 was the 2023 list price for a 30-day supply; $231 is the negotiated price Medicare has paid since January 1, 2026 — the first negotiated prices in the program's history. Ten drugs took cuts of 38–79% (Januvia the deepest at 79%), an estimated $1.5 billion back in beneficiaries' pockets. Nothing about the pills changed. | CMS (effective Jan 2026) |
| The middlemen — PBMs | ~80% of 6.6B prescriptions | Three pharmacy benefit managers processed nearly 80% of the 6.6 billion prescriptions Americans filled in 2023 — each inside a conglomerate that also owns a major insurer and its own pharmacies (FTC, 2024). Per the FTC's complaint, they are paid rebates calculated as a percentage of the list price: the higher the sticker, the bigger the cut, with no extra service provided. FTC investigators also reported their affiliated pharmacies collected an estimated $7.3 billion above drug acquisition cost on specialty generics, 2017–2022. | FTC reports (2024–2025) |
| The counter — your copay | ~4× what plans paid | Government auditors found Part D copays are calculated on the gross price before rebates. On 79 of the 100 most-rebated drugs, patients collectively paid about 4 times what their plans paid net (GAO, 2021 data) — while roughly $48.6 billion in manufacturer rebates flowed back through Medicare drug plans that same year. | GAO (2021 data) |
| The drift — list vs net | +159% vs +60% | One peer-reviewed analysis tracked branded drugs from 2007 to 2018: list prices rose 159% while the net prices actually paid rose 60% (JAMA). US brand-name prices ran 4.22× the average of 33 other countries — yet US unbranded generics sat at 67% of the international average, cheaper than the world's (RAND/ASPE, 2022 data). Where competition reaches, the system produces fair prices. | JAMA (2007–2018) · RAND/ASPE (2022 data) |
| The wall — patents | 132 patents on one drug | Humira was shielded by 132 granted patents; Europe got biosimilar copies in 2018 while Americans waited until 2023, after its US price had climbed roughly 470% (Nature Biotechnology · House Oversight). One study found 78% of new drug-patent protections went to existing drugs, and regulators have challenged over 400 improper Orange Book patent listings since 2023 — a single wrong listing can freeze a generic for 30 months (FTC). | Nature Biotech · House Oversight · FTC |
| The catch — who feels it | Medicare-first | Fifteen more negotiated prices follow in January 2027, semaglutide among them (CMS). A February 2026 law de-links PBM Medicare pay from list prices starting 2028 and requires 100% rebate pass-through to employer plans. But it starts with Medicare — most prescriptions won't feel it today, and about 30% of Americans still reported rationing or skipping doses due to cost (FTC, 2024 report). | CMS · P.L. 119-75 (Feb 2026) · FTC |
We compare what prescriptions cost and how those numbers were set — not what anyone should take, start, stop, or switch. Treatment decisions belong with you, your pharmacist, and a licensed prescriber.
The sticker and the real price parted ways a generation ago. A peer-reviewed JAMA analysis tracked branded drugs for eleven years, 2007–2018: list prices rose 159% while the prices actually paid — after the discounts nobody sees — rose 60%. The person the sticker still binds is the patient: government auditors found Part D copays were calculated on the gross price before rebates, and on 79 of the 100 most-rebated drugs, patients collectively paid about 4 times what their plans paid net (GAO, 2021 data). The discount was real. It just wasn't for them.
The mechanism came out in a federal complaint: the companies that decide which drugs insurance covers are paid rebates calculated as a percentage of the list price — the higher the sticker, the bigger their cut, with no extra service provided (FTC). Three of those companies processed nearly 80% of the 6.6 billion prescriptions Americans filled in 2023, each inside a conglomerate that also owns a major insurer and its own pharmacies. FTC investigators further reported that pharmacies owned by those three marked up specialty generics — cancer pills, transplant drugs — by hundreds, sometimes thousands of percent, collecting an estimated $7.3 billion above acquisition cost between 2017 and 2022. In February 2026, one of the three settled with the FTC, agreeing to price patients' shares on the net number rather than the sticker.
A bluff this large survives only where competition can't reach — and the door was locked with patents. Humira, for years the world's best-selling drug, was shielded by 132 granted patents; Europe got biosimilar copies in 2018 while Americans waited until 2023, by which point its US price had climbed roughly 470% (Nature Biotechnology · House Oversight). One study found 78% of new drug-patent protections went to existing drugs — new shell, old medicine, the same pattern this channel documented in the $608 EpiPen and the $497 inhaler whose patents reportedly sit on the plastic device. The FTC once estimated pay-for-delay deals cost consumers about $3.5 billion a year, and since 2023 regulators have challenged more than 400 improper Orange Book patent listings — because a single wrong listing can freeze a generic for 30 months. Meanwhile, US unbranded generics sold at 67% of the international average (RAND/ASPE, 2022 data): where competition reached, the system produced fair prices.
The first ten negotiated Medicare prices took effect January 1, 2026 — cuts of 38 to 79%, an estimated $1.5 billion back in beneficiaries' pockets, with Eliquis's $521-to-$231 drop the headline case (CMS). Fifteen more drugs follow in January 2027, semaglutide among them. And a February 2026 law ordered the rebate game unwound: from 2028, PBM pay in Medicare is de-linked from list prices, and every rebate must reach the employer's plan. The honest asterisk stays: it starts with Medicare, most prescriptions won't feel it today, and about 30% of Americans still reported rationing or skipping doses due to cost (FTC, 2024 report).
This capstone didn't start from theory. Each mechanism above was documented drug-by-drug in this series first — five cost investigations, each with its own dated sources. They are the evidence; this page is the machine they add up to.
No single actor. Manufacturers set the list price, pharmacy benefit managers negotiate rebates calculated as a percentage of that list, and insurers set the patient's share. The FTC's complaint notes that higher stickers mean bigger rebates for the middlemen, with no extra service provided — so everyone in the chain profited from a higher sticker except the person at the counter.
A PBM decides which drugs your insurance covers. Three of them processed nearly 80% of the 6.6 billion prescriptions Americans filled in 2023 — each inside a conglomerate that also owns a major insurer and its own pharmacies (FTC, 2024).
Government auditors found Medicare Part D copays are calculated on the gross price before rebates. On 79 of the 100 most-rebated drugs, patients collectively paid about 4 times what their plans paid net (GAO, 2021 data), while about $48.6 billion in manufacturer rebates flowed through Part D plans that year.
Medicare's first ten negotiated prices took effect January 1, 2026 — cuts of 38–79%, with Eliquis falling from a $521 list price to $231 and an estimated $1.5 billion back in beneficiaries' pockets (CMS). Fifteen more drugs follow in 2027, semaglutide included, and a February 2026 law de-links PBM pay from list prices in Medicare starting 2028, with 100% rebate pass-through to employer plans.
Patents — often on delivery devices or minor variations rather than the medicine itself. Humira carried 132 granted patents, and US biosimilars arrived 5 years after Europe's (Nature Biotechnology). One study found 78% of new drug-patent protections went to existing drugs, and regulators have challenged over 400 improper patent listings since 2023 (FTC).
No — and that's the tell. US brand-name drug prices ran 4.22× the average of 33 other countries, but US unbranded generics sat at 67% of the international average — cheaper than the world's (RAND/ASPE, 2022 data). Where real competition reaches, the American system produces fair prices; the gap lives where it can't.
About 30% of Americans reported rationing or skipping doses due to cost (FTC, 2024 report). The 2026 negotiated prices start with Medicare, so most prescriptions won't feel them immediately. Cost information, not medical advice — treatment decisions belong with you and a licensed prescriber.
Wellness Vision does not sell medication, book trips, or take referrals. Every figure above traces to the public sources cited — federal fact sheets, FTC staff reports and complaint filings, GAO audits, peer-reviewed journals, and congressional records. This is a cost and policy explainer, not medical advice: nothing here tells anyone to start, stop, switch, or ration a medication, and treatment decisions belong with you, your pharmacist, and a licensed prescriber.
📋 Or get the free Medical Cost Checklist — no email →
View provenance manifest for this video →
You shouldn't have to go broke to feel whole.
